// App-Quantinova.ai

4523 : Atezolizumab (atezo) in first-line cisplatin-ineligible or platinum-treated locally advanced or metastatic urothelial cancer (mUC): Long-term efficacy from phase 2 study IMvigor210.

Researchers

Presenter

  • Arjun Vasant Balar

Principal Investigators

  • Robert Dreicer

  • Yohann Loriot

  • Jose Luis Perez-Gracia

  • Jean H. Hoffman-Censits

  • Daniel Peter Petrylak

  • Michiel Simon Van Der Heijden

  • Beiying Ding

  • Xiaodong Shen

  • Jonathan E. Rosenberg

Medical Centers

  • Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, NY

  • University of Virginia Emily Couric Clinical Cancer Center, Charlottesville, VA

  • Gustave Roussy, Villejuif, France

  • Clinica Universidad de Navarra, Pamplona, Spain

  • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD

  • Yale University School of Medicine, New Haven, CT

  • Department of Radiation Oncology, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Ziekenhuis, Amsterdam, Netherlands

  • Genentech, Inc., South San Francisico, CA

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

Locations

  • United States

  • Spain

  • France

  • Netherlands

Companies

  • Genentech, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Atezolizumab

  • Cisplatin

Outcome

  • Indeterminate

Study Design

  • Cohort

Phase

  • II

Study Id's

  • NCT02302807

  • NCT02951767

  • NCT02108652

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved